ProPharma simplifies access to Cell and Gene Therapies by offering empathetic, personalized support across every stage of the treatment journey. From financial navigation to emotional assistance, our comprehensive Patient Support Programs ensure patients can focus on what truly matters: their health. Discover how our dedicated case managers and global support network make complex treatments more accessible and successful. Read our blog to find out more: https://lnkd.in/egMgSVeA. #CAGT
ProPharma’s Post
More Relevant Posts
-
Science marketers, is time scarcity preventing you from delivering marketing excellence? Do you want to drive growth in these challenging times? Do you want to deliver an impressive project in the next 12 months?
#longevitymedicine and compliance of #cellandgenetherapy #webinaralert Don't miss this panel live in 6 days' time, but even if you can't make it, register anyway and you'll receive a link to watch on demand.
Save the date! Attend our forum with SelectScience on Feb 27 at 16:00 GMT for a deep dive into the longevity and compliance of cell and gene therapies. We'll cover key topics like safety, efficacy, manufacturing and regulatory hurdles. Whether you're a researcher, healthcare pro, or industry enthusiast, gain insights into the future of medicine. Register here: https://hubs.li/Q02ll5Df0
To view or add a comment, sign in
-
-
Barriers to patient access vary widely by area. For example, cell and gene therapies are limited by restrictive PA criteria, inadequate reimbursement, site-level capacity challenges and referral gaps. See the four key points from our #MarketAccess research in this blog: https://ow.ly/4QOW50RZ2BA
To view or add a comment, sign in
-
Managing Director at MESLO | Distribution Network Specialist | Water and Life Science Enthusiast | Passionate about Water Quality and Viruses
Exciting Event Alert: Accelerating Science Forum on Longevity and Compliance in Cell and Gene Therapies! 🧬 Join us for a groundbreaking online forum dedicated to the future of healthcare - exploring the latest advancements in cell and gene therapies. Discover how we're tackling longevity and compliance, pushing the boundaries of science to pave the way for new treatments and therapies that could transform lives. 📅 Don't miss this opportunity to connect with leading experts, gain insights into cutting-edge research, and be part of the conversation shaping the future of medicine. Whether you're a scientist, healthcare professional, or just passionate about the next frontier in healthcare innovation, this event is for you. 💡 Learn from the pioneers driving forward these revolutionary therapies, engage in meaningful discussions, and network with professionals from across the globe - all from the comfort of your home or office. Register now to secure your spot in this not-to-be-missed forum and be at the forefront of accelerating science in cell and gene therapies! #CellTherapy #GeneTherapy #HealthcareInnovation #ScienceForum #Longevity #Compliance #MedicalResearch #OnlineEvent
Save the date! Attend our forum with SelectScience on Feb 27 at 16:00 GMT for a deep dive into the longevity and compliance of cell and gene therapies. We'll cover key topics like safety, efficacy, manufacturing and regulatory hurdles. Whether you're a researcher, healthcare pro, or industry enthusiast, gain insights into the future of medicine. Register here: https://hubs.li/Q02ll5Df0
To view or add a comment, sign in
-
-
How many treatment-eligible people are likely to treat and how long before they treat? Ask PAM! The NEWDIGS Pipeline Analytics Model (PAM) helps you assess the numbers by payer type and population size—for the recently-approved sickle cell treatments and over 800 other approved or pipeline cell and gene therapy products. This edition of Ask PAM shows you how stakeholders, such as commercial payers, care providers, self-insured employers, and developers might estimate how many people who meet FDA label criteria are likely to be treated, and how soon. https://lnkd.in/eekheqgm
To view or add a comment, sign in
-
How can we meet the increasing demand for cell and gene therapies? These therapies, while powerful, are difficult to manufacture due to their inherent variability. In this recent, collaborative whitepaper for BioProcess International, our Director and Head of Product Development Kumud Raj Poudel, contributes to the discussion of the main challenges at hand and how we can overcome them. Please read the full article to explore this insightful commentary: https://bit.ly/3utkYQj
To view or add a comment, sign in
-
Scaling up a supply chain for cell and gene therapies brings its own unique complexities that product sponsors need to consider. Download the white paper to learn how to scale up logistics and storage capabilities to serve an increasing number of patients, and to accommodate the new stakeholders that join the supply chain post-commercialization. http://ow.ly/EzNP50HyKJl #clinicaltrials #AdvancedTherapies #CellTherapy #GeneTherapy
To view or add a comment, sign in
-
-
The complexity of the infrastructure required to support cell and gene therapies necessitates early consideration of supply chain issues, even before entering human studies. In this interview, Tobias Handschuh sits down with Vice President of Scientific Affairs at TrakCel, Matthew Lakelin, to discuss the requirements for ensuring the safe, efficient, and timely delivery of cell and gene therapies to patients. Watch the full interview here > https://owy.mn/4dfy0SY #OWHealth #healthcare #SupplyChain
Managing Uncertainties In Cell And Gene Therapy Supply Chain
To view or add a comment, sign in
-
Embark on a Decade of Breakthroughs with DS InPharmatics! 🚀 Over the past ten years, the approval of cell and gene therapies has paved the way for extraordinary health outcomes for patients. 🌐💊 Curious about the FDA's role in guiding companies through the CMC requirements process for these groundbreaking therapies? 🧬🛠️ Dive into the details and elevate your understanding: https://bit.ly/3Hk9elP Stay informed, stay inspired! Let DS InPharmatics be your guide to the future of healthcare. 💙 #DSIGeneTherapies #HealthcareInnovation #FDAApprovals
To view or add a comment, sign in
-
-
Dive into the exciting world of decentralized supply chains for cell and gene therapies (CGTs) with Jennifer Fenwick and Matthew Lakelin from TrakCel. They've unpacked why digital integration in your supply chain is a game-changer, and how choosing your partners wisely could be the key to success. Plus, discover why there's a shift toward decentralization in clinical trials for CGTs. Intrigued? Access their insightful full Q&A: https://lnkd.in/edqjc7E2
To view or add a comment, sign in
-
-
Dive into the exciting world of decentralized supply chains for cell and gene therapies (CGTs) with Jennifer Fenwick and Matthew Lakelin from TrakCel. They've unpacked why digital integration in your supply chain is a game-changer, and how choosing your partners wisely could be the key to success. Plus, discover why there's a shift toward decentralization in clinical trials for CGTs. Intrigued? Access their insightful full Q&A: https://lnkd.in/edqjc7E2
To view or add a comment, sign in
-